Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tigris Pharmaceuticals, a drug development company, has announced that its investigational new drug application for the company's geranylgeranyltransferase inhibitor has been accepted by the FDA.
Subscribe to our email newsletter
This will allow the company to open a Phase I study evaluating the safety of GGTI-2418 during the first quarter of 2009. GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that induces apoptosis by downregulating several pivotal oncogenic and tumor survival pathways.
Tigris has in-licensed the exclusive worldwide rights to GGTI-2418 from Yale University and the University of South Florida.
Edmundo Muniz, president and CEO of Tigris, said: “We are excited to reach this important corporate milestone and to advance this novel, targeted compound into the clinic.
“We look forward to completing the Phase I study of GGTI-2418 in two top Phase I cancer research centers and to continuing our rapid development of this agent. This is the first geranylgeranyltransferase inhibitor to move to clinical phase studies.”